- Home
- REPL vs URGN Comparison
REPL vs URGN Comparison
Compare REPL & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- URGN
- Stock Information
- Founded
- REPL 2015
- URGN 2004
- Country
- REPL United States
- URGN United States
- Employees
- REPL N/A
- URGN N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- REPL Health Care
- URGN Health Care
- Exchange
- REPL Nasdaq
- URGN Nasdaq
- Market Cap
- REPL 649.1M
- URGN 463.2M
- IPO Year
- REPL 2018
- URGN 2017
- Fundamental
- Price
- REPL $9.63
- URGN $5.00
- Analyst Decision
- REPL Strong Buy
- URGN Strong Buy
- Analyst Count
- REPL 7
- URGN 8
- Target Price
- REPL $20.29
- URGN $22.92
- AVG Volume (30 Days)
- REPL 1.7M
- URGN 2.8M
- Earning Date
- REPL 05-22-2025
- URGN 05-12-2025
- Dividend Yield
- REPL N/A
- URGN N/A
- EPS Growth
- REPL N/A
- URGN N/A
- EPS
- REPL N/A
- URGN N/A
- Revenue
- REPL N/A
- URGN $91,871,000.00
- Revenue This Year
- REPL N/A
- URGN $30.00
- Revenue Next Year
- REPL N/A
- URGN $102.76
- P/E Ratio
- REPL N/A
- URGN N/A
- Revenue Growth
- REPL N/A
- URGN 8.98
- 52 Week Low
- REPL $4.93
- URGN $3.42
- 52 Week High
- REPL $17.00
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- REPL 58.72
- URGN 34.53
- Support Level
- REPL $8.25
- URGN $3.61
- Resistance Level
- REPL $10.16
- URGN $4.25
- Average True Range (ATR)
- REPL 0.92
- URGN 0.74
- MACD
- REPL 0.21
- URGN -0.18
- Stochastic Oscillator
- REPL 84.04
- URGN 21.41
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.